DoctorMark Ambrose

Senior Lecturer in Medical Microbiology

Medicine

  • Senior Lecturer in Medical Microbiology
    Medicine
  • +61 3 6226 4669 (Work)
  • Tasmanian School of Medicine, Medicine, 240-02 (Level 2) Medical Sciences 1, Hobart CBD Campuses, TAS

FUNDED PROJECTS

  • GRANT
    Processes regulating biofilm dispersal impact the mutability of the cystic fibrosis pathogen Pseudomonas aeruginosa
    1 Jan 2023 - 31 May 2024
    People funded by this grant:
    • Ambrose M
    Project Total: $22,545; People with cystic fibrosis (CF) develop lung infection by the bacterium Pseudomonas aeruginosa, which escapes antibiotics because of its ability to form resistant biofilm in the airways of people with CF. Investigators are developing anti-biofilm (dispersal) therapeutic strategies to improve the antibiotic susceptible of the bacterial cells, however, the impact of biofilm dispersal on the mutability of this organism in the presence of antibiotics has been poorly investigated, and hence is not fully understood. Our working hypothesis is that biofilm dispersal by P. aeruginosa is intrinsically linked to the operation(s) of its mutation generation system(s), and that this nexus has important implications for how investigators approach the development of anti-biofilm (dispersal) therapeutics. Funded by: The MPST Foundation Ltd - Grant ($22,545); University of Tasmania.
  • GRANT
    Pre-clinical toxicity assessment to select drug development candidates against mitochondrial dysfunction
    1 Feb 2020 - 1 Feb 2022
    People funded by this grant:
    • Guven N,
    • Smith J,
    • Ambrose M
    Project Total: $144,300; This application supports a valley of death? project to generate the pre-clinical toxicity data that are required towards commercialisation of UTAS-derived novel drug candidates Funded by: National Foundation for Medical Research and Innovation - Grant-Expression of Interest ($144,300); University of Tasmania.
  • GRANT
    Characterisation of newly identified Pandoraea isolates from paediatric Tasmanian CF patients
    1 Jan 2020 - 30 Jun 2021
    People funded by this grant:
    • Roddam L,
    • Ambrose M,
    • Pagnon J,
    • McEwan B,
    • Beggs S
    Project Total: $8,550; Pandoraea, an emerging bacterial pathogen, is highly antibiotic resistant and was first isolated from a Tasmanian CF patient in 2012, then again in 2018 from two Tasmanian paediatric patients. We will characterise these new isolates (determine species, antibiotic resistance profiles and virulence potential) to advance our understanding of this pathogen. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($8,550); University of Tasmania.
  • GRANT
    Characterising the regulation of antibiotic resistance mutations in the cystic fibrosis pathogen Pseudomonas aeruginosa
    1 Jan 2020 - 30 Apr 2021
    People funded by this grant:
    • Ambrose M
    Project Total: $25,000; People with cystic fibrosis (CF) develop lung infection by the bacterium Pseudomonas aeruginosa, which escapes antibiotic treatment and eventually becomes permanently established in the airways of people with CF. How this organism resists antibiotic challenges is not yet fully understood. Our working hypothesis is that P. aeruginosa evolves through antibiotic challenges by accumulating resistance mutations via a metabolically-sensitive mutation generation pathway, whose regulation we believe represents an underexplored therapeutic target. Funded by: The MPST Foundation Ltd - Grant ($25,000); University of Tasmania.
  • GRANT
    Cystic Fibrosis: Investigating the acute stage of infection by Pseudomonas aeruginosa
    1 Jan 2018 - 30 Jun 2019
    People funded by this grant:
    • Ambrose M,
    • Beggs S
    Project Total: $10,000; Cystic fibrosis (CF) patients develop chronic lung infection by the bacterium Pseudomonas aeruginosa, which are resistant to antibiotic treatment. We need to target the early (acute) stage of infection by this organism, and we will use primary CF epithelial cells and P. aeruginosa gene arrays to identity potential bacterial targets. Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($10,000); University of Tasmania.
  • GRANT
    Non-conventional antimicrobial testing of emerging pathogens
    1 Jan 2017 - 30 Jun 2018
    People funded by this grant:
    • Roddam L,
    • Beggs S,
    • Ambrose M,
    • Malley R
    Project Total: $10,000; Pandoraea, is an emerging bacterial pathogen of cystic fibrosis. Conventional antibiotic susceptibility testing shows Pandoraea to be multi-drug resistant with limited treatment options. We will investigate the antibiotic susceptibility of Pandoraea using non-conventional methods to determine if we are underestimating treatment options for this chronic infection. Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($10,000); University of Tasmania.
  • GRANT
    Molecular profiling of the post radiotherapy chromatin landscape in prostate cancer cells
    31 Jan 2016 - 30 Jun 2017
    People funded by this grant:
    • Brettingham-Moore K,
    • Ambrose M,
    • Holloway A,
    • Skala M,
    • Taberlay P
    Project Total: $33,000; This project will investigate the basal and post radiotherapy epigenetic changes in prostate cancer cells with divergent response to radiotherapy (RT). It will validate methylation data obtained from illumina Infinium 450 beadchip arrays, profile histone modifications post RT and investigate DNA damage post RT in cells treated with inhibitors of epigenetic enzymes (DNMT and HDAC). Funded by: Cancer Council of Tasmania - Grant-Cancer Research ($33,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Anti-inflammatory efficacy of Marinovas Fucoidan & interactions with microbiota
    1 Jan 2016 - 18 Apr 2017
    People funded by this grant:
    • Guven N,
    • Eri R,
    • Ahuja K,
    • Ball M,
    • Ambrose M
    Project Total: $100,000; Industry interaction to develop Marinova's fucoidan extracts for gut health Funded by: Department of Industry, Innovation and Science ($50,000); Marinova Pty Ltd ($50,000); University of Tasmania.
  • GRANT
    Prevalence and virulence of an emerging bacterial pathogen of Tasmanian cystic fibrosis patients
    1 Mar 2015 - 28 Feb 2016
    People funded by this grant:
    • Roddam L,
    • Ambrose M,
    • Beggs S,
    • Cooley M,
    • Malley R
    Project Total: $11,100; Pandoraea, an emerging bacterial pathogen of cystic fibrosis is difficult to identify, is of unknown clinical significance and was recently isolated from a Tasmanian CF patient. we will investigate the prevalence of Pandoraea in Tasmanian CF patients, describe its virulence potential and investigate its susceptilility to our new antimicrobial therapy. Funded by: Royal Hobart Hospital Research Foundation - Grant-Clinical Research ($11,100); University of Tasmania.
  • GRANT
    A human paraoxonase 2-based therapy for cystic fibrosis A
    31 Oct 2014 - 30 Apr 2018
    People funded by this grant:
    • Roddam L,
    • Cooley M,
    • Ambrose M
    Project Total: $15,000; Cystic Fibrosis (CF) is the most common genetic condition affecting Australians. People with CF carry a mutation in a gene, which is essential for maintaining the proper balance of salt and water in lungs. As a result, CF patients experience a continuous build-up of thick and sticky mucous in their lungs, which can be colonised by many different types of microorganisms, and especially by Pseudomonas aeruginosa. Infections by P. aeruginosa cannot be completely eradicated using currently available antibiotics because cells of this organism can group together to live in so-called biofilms (which are essentially protected cell communities), which antibiotics simply fail to penetrate successfully. This project will investigate ways to make P. aeruginosa more susceptible to existing antibiotics. The approach aims to prevent/disrupt the grouping together of individual bacterial cells in the first instance, thereby allowing the antibiotics to kill them more effectively. Current research is producing in the laboratory a human anti-biofilm enzyme, known as human paraoxonase 2 (PON2). PON2 is usually produced inside of human cells, which means it is not able to attack the bacterial cells that usually live outside human cells. By administering the recombinant human PON2 (as an aerosol, for example), together with certain antibiotics, it is anticipated that prevention and/or eradication of P. aeruginosa infections will be possible in people with CF. Funded by: Australian Cystic Fibrosis Research Trust - Scholarship-Top-Up ($15,000); University of Tasmania.
  • GRANT
    Testing a new therapy against lung infections for people with cystic fibrosis
    1 Jan 2014 - 31 Oct 2015
    People funded by this grant:
    • Roddam L,
    • Cooley M,
    • Ambrose M,
    • Tristram S
    Project Total: $67,782; P. aeruginosa uses small diffusible signal molecules called acyl-homoserine lactones (AHLs) to alter its growth, which enables it to hide from antibiotic therapies and the immune system of the host thereby preventing its eradication from the lungs. These bacterial AHL molecules can also enter and affect human cells leading to further lung damage. This project aims to demonstrate that a novel therapy that inactivates bacterial AHLs can protect human cells from these molecules. Demonstration of this is the first step in showing that this therapy can protect the lungs of people with CF from P. aeruginosa infections. In summary, this new treatment approach should at a minimum prevent a significant amount of the lung damage that occurs, resulting in better quality of life and increased life span. More importantly, this therapy also has the potential to prevent P. aeruginosa lung infections in CF. Funded by: Clifford Craig Foundation - Grant ($67,782); University of Tasmania.